UNSPSC 51182439: Teriparatide recombinant human

This classification denotes a recombinant parathyroid hormone with the molecular formula C181H291N55O51S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10T9CSU89I, chemically known as l-phenylalanine, l-seryl-l-valyl-l-seryl-l-alpha-glutamyl-l-isoleucyl-l-glutaminyl-l-leucyl-l-methionyl-l-histidyl-l-asparaginyl-l-leucylglycyl-l-lysyl-l-histidyl-l-leucyl-l-asparaginyl-l-seryl-l-methionyl-l-alpha-glutamyl-l-arginyl-l-valyl-l-alpha-glutamyl-l-tryptophyl-l-leucyl-l-arginyl-l-lysyl-l-lysyl-l-leucyl-l-glutaminyl-l-alpha-aspartyl-l-valyl-l-histidyl-l-asparaginyl- but more generally known as teriparatide, which bears US NIH Compound Identifier 16129682.

UNSPSC 51182439 Teriparatide recombinant human is a Commodity code encompassing injectable pharmaceutical products used to treat osteoporosis and related bone-loss conditions. State and local procurement activity under this code centers on multi-source generic pharmaceuticals and over-the-counter products distributed through cooperative purchasing arrangements to government facilities, health systems, and public institutions. Issuing bodies include state health and human services departments, cooperative purchasing alliances, and state procurement offices that aggregate demand across participating jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary vehicle for centralizing pharmaceutical procurement across member states and localities. Vendors supplying under this code must maintain current Good Manufacturing Practices (cGMP) certification, comply with FDA requirements and the Drug Supply Chain Security Act (DSCSA), and establish relationships with authorized pharmaceutical wholesalers such as AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC to fulfill chargeback systems and deliver products to end-user facilities.

Recent activity shows concentration in the Upper Midwest and Pacific Northwest, with MMCAP's RFP issued January 20, 2026 covering Minnesota and Oregon participation. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 on January 20, 2026 with proposals due March 26, 2026, seeking multiple contract awards for generic multi-source pharmaceuticals and OTC products effective July 1, 2026 through June 30, 2028. Evaluation weights 75 percent on price competitiveness, with 10 percent on fixed pricing, 5 percent on administrative compliance, 5 percent on EDI capability, and 5 percent on willingness to accept a 3 percent administrative fee. Vendors must carry commercial general liability insurance of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million. No specific dollar value or budget range is disclosed; however, performance penalties of $200 to $1,500 per violation apply for reporting delays, missed onboarding, or improper class-of-trade denials. Submissions require use of the ePro procurement system and Google Chrome, with pricing delivered in Excel-to-CSV format to MMCAP_Infuse.RFP@state.mn.us, and the RFP identifies no set-aside designations restricting responses to particular business classifications.